advertisement
Abstract #8960 Published in IGR 5-2
Comparison of the efficacy of the fixed-combination timolol/dorzolamide versus concomitant administration of timolol and dorzolamide
Bacharach J; Delgado MF; Iwach AGJournal of Ocular Pharmacology and Therapeutics 2003; 19: 93-96
The purpose of this study was to compare the efficacy of the fixed-combination solution of timolol 0.5%/dorzolamide 2% with the concomitant administration of its components, timolol 0.5% twice a day and dorzolamide 2% twice a day. Ninety-eight patients adequately controlled with a concomitant regimen of timolol and dorzolamide were switched to the fixed-combination regimen of the same components. Intraocular pressure (IOP) at baseline and four weeks after the change in regimen were recorded. Mean baseline IOP was 16.0 ± 5.6 mmHg. Four weeks after the change in medication to the fixed-combination regimen, mean IOP was 14.5 ± 5.6 mmHg. Mean IOP change from baseline was -1.5 ± 3.9 mmHg. The difference between the two treatment modalities was found to be statistically significant (p < 0.001). Eighty-one (83%) patients were considered successfully switched after four weeks of fixed-combination therapy, and 17 eyes (17%) were deemed unsuccessful because a rise in IOP was detected. In conclusion, the fixed combination of timolol 0.5%/dorzolamide 2% twice a day provided equivalent or better IOP reduction in most patients who were successfully controlled on concomitant administration of its components, timolol and dorzolamide.
Dr. J. Bacharach, North Bay Eye Associates, Inc. Petaluma, CA 94954, USA. jbiop@cds1.net
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
